These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Design, synthesis and antithrombotic evaluation of novel dabigatran etexilate analogs, a new series of non-peptides thrombin inhibitors. Chen D; Wang S; Diao X; Zhu Q; Shen H; Han X; Wang Y; Gong G; Xu Y Bioorg Med Chem; 2015 Dec; 23(23):7405-16. PubMed ID: 26537784 [TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo properties of bicyclic lactam inhibitors: a novel class of low molecular weight peptidomimetic thrombin inhibitors. Leblond L; Grouix B; Boudreau C; Yang Q; Siddiqui MA; Winocour PD Thromb Res; 2000 Nov; 100(3):195-209. PubMed ID: 11108907 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and Biological Evaluation of Some New 2,5-Substituted 1-Ethyl-1H-benzoimidazole Fluorinated Derivatives as Direct Thrombin Inhibitors. Li M; Ren Y Arch Pharm (Weinheim); 2015 May; 348(5):353-65. PubMed ID: 25824648 [TBL] [Abstract][Full Text] [Related]
8. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban. Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603 [TBL] [Abstract][Full Text] [Related]
9. VE-1902-A direct thrombin inhibitor with reversible covalent mechanism of action shows efficacy with reduced bleeding in rodent models of thrombosis. Sivaraja M; Clemens DM; Sizikov S; Dash S; Xu C; Rienzo M; Yang B; Ryan M; Chattopadhyay M; Igoudin L; Chang SS; Keutzer S; Zalicki P; Estiarte MA; Shiau TP; Short KM; Williams DC; Datta A; Pozzi N; Di Cera E; Gibson CM; Fox KAA; Kita DB Thromb Res; 2020 Jun; 190():112-121. PubMed ID: 32339947 [TBL] [Abstract][Full Text] [Related]
10. Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenylalanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis. Jackson CV; Crowe VG; Frank JD; Wilson HC; Coffman WJ; Utterback BG; Jakubowski JA; Smith GF J Pharmacol Exp Ther; 1992 May; 261(2):546-52. PubMed ID: 1578372 [TBL] [Abstract][Full Text] [Related]
11. S35972, a direct-acting thrombin inhibitor with high oral bioavailability and antithrombotic efficacy. Rupin A; Marx I; Vallez MO; Mennecier P; Gloanec P; De Nanteuil G; Verbeuren TJ J Thromb Haemost; 2011 Jul; 9(7):1375-82. PubMed ID: 21481181 [TBL] [Abstract][Full Text] [Related]
12. Selection of S18326 as a new potent and selective boronic acid direct thrombin inhibitor. Rupin A; Mennecier P; Lila C; de Nanteuil G; Verbeuren TJ Thromb Haemost; 1997 Oct; 78(4):1221-7. PubMed ID: 9364988 [TBL] [Abstract][Full Text] [Related]
13. Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits. Wong PC; Crain EJ; Watson CA; Xin B J Thromb Haemost; 2009 Aug; 7(8):1313-20. PubMed ID: 19500242 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of direct thrombin inhibitors bearing 4-(piperidin-1-yl)pyridine at the P1 position with potent anticoagulant activity. de Candia M; Fiorella F; Lopopolo G; Carotti A; Romano MR; Lograno MD; Martel S; Carrupt PA; Belviso BD; Caliandro R; Altomare C J Med Chem; 2013 Nov; 56(21):8696-711. PubMed ID: 24102612 [TBL] [Abstract][Full Text] [Related]
15. Antithrombotic activity of HY023016, a novel Dabigatran prodrug evaluated in animal thrombosis models. Li YZ; Gong GQ; Yang WH; Wang XH; Jiang ML; Zhou Y; Yang XZ; Xu YG; He GW Thromb Res; 2013 May; 131(5):425-35. PubMed ID: 23535565 [TBL] [Abstract][Full Text] [Related]
16. Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus? Lippi G; Favaloro EJ Clin Chem Lab Med; 2015 Feb; 53(2):185-97. PubMed ID: 25241734 [TBL] [Abstract][Full Text] [Related]
17. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study. Testa S; Legnani C; Tripodi A; Paoletti O; Pengo V; Abbate R; Bassi L; Carraro P; Cini M; Paniccia R; Poli D; Palareti G J Thromb Haemost; 2016 Nov; 14(11):2194-2201. PubMed ID: 27566988 [TBL] [Abstract][Full Text] [Related]
18. Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate. Dinkelaar J; Patiwael S; Harenberg J; Leyte A; Brinkman HJ Clin Chem Lab Med; 2014 Nov; 52(11):1615-23. PubMed ID: 24902009 [TBL] [Abstract][Full Text] [Related]
19. New Route to the Synthesis of Novel Pyrazolo[1,5-a]pyrimidines and Evaluation of their Antimicrobial Activity as RNA Polymerase Inhibitors. Abdallah AEM; Elgemeie GH Med Chem; 2022; 18(9):926-948. PubMed ID: 35236270 [TBL] [Abstract][Full Text] [Related]
20. Differential effects of direct factor IIa and factor Xa inhibitors in protein C-deficient plasma detected using thrombin generation and viscoelastometry assays. Aungraheeta R; FitzGibbon L; Reilly-Stitt C; Mumford AD Int J Lab Hematol; 2020 Apr; 42(2):126-133. PubMed ID: 31756037 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]